A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy

被引:7
|
作者
Crossnohere, Norah L. [1 ]
Fischer, Ryan [2 ]
Vroom, Elizabeth [3 ]
Furlong, Patricia [2 ]
Bridges, John F. P. [1 ]
机构
[1] Ohio State Univ, Dept Biomed Informat, Coll Med, Lincoln Tower,1800 Cannon Dr, Columbus, OH 43210 USA
[2] Parent Project Muscular Dystrophy, Washington, DC USA
[3] Duchenne Parent Project, Amsterdam, Netherlands
来源
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH | 2022年 / 15卷 / 05期
关键词
DISCRETE-CHOICE EXPERIMENTS; HEALTH-CARE; EMERGING THERAPIES; LIFE; HETEROGENEITY;
D O I
10.1007/s40271-022-00574-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background and Objectives Caregivers routinely inform medical and regulatory decision making in rare pediatric diseases. While differences in treatment preferences across caregivers and patients have been observed for Duchenne muscular dystrophy, this evidence was limited by small samples of patients and results were confounded by patient age and disease progression. We tested caregiver and patient preference concordance for treating Duchenne. Methods Preferences and demographic/clinical information from 115 caregivers and 107 patients were collected in an international study (response = 80%) using a previously developed discrete-choice experiment consisting of 12 experimentally controlled choice tasks. Each task presented two profiles that varied across four attributes: disease progression, drug failure probability, kidney damage risk, and fracture risk. Caregivers and patients were matched 1:1 based on patient age. We tested for concordance across each task and by comparing caregivers' and patients' maximum acceptable risk of drug failure, kidney damage, and fracture for a slowing of disease progression. Results The final analysis included 77 caregivers and 77 patients. No differences were observed in nationality (p = 0.969), disease stage (p = 0.180), or demographic/clinical factors (p = 0.093-0.857); however, patients were more optimistic (p = 0.030). Caregivers and patients chose similarly across tasks (p = 0.101-0.993). To slow disease progression by 1 year, caregivers and patients would tolerate a 9% and 11% increase in drug failure probability, respectively (p = 0.267). Alternatively, they would accept a 3% and 4% increase in the risk of kidney damage (p = 0.719) or a 15% and 20% increase in the risk of fracture (p = 0.534). Conclusions Caregivers and patients had concordant preferences for treating Duchenne. Providers and regulators can trust both caregiver and patient report of preferences to inform medical decision making.
引用
收藏
页码:577 / 588
页数:12
相关论文
共 50 条
  • [1] A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy
    Norah L. Crossnohere
    Ryan Fischer
    Elizabeth Vroom
    Patricia Furlong
    John F. P. Bridges
    The Patient - Patient-Centered Outcomes Research, 2022, 15 : 577 - 588
  • [2] Patient and Caregiver Preferences for the Treatment of Duchenne Muscular Dystrophy: A Quantitative Patient Preference Study
    Desmet, T.
    van Haesendonck, L.
    De Waele, L.
    Geuens, S.
    Herman, A.
    Heslop, E.
    Simoens, S.
    Janssens, R.
    Huys, I
    VALUE IN HEALTH, 2022, 25 (12) : S396 - S396
  • [3] Beyond the skeletal muscle: Caregiver and patient preferences for treatment targets for Duchenne/Becker muscular dystrophy
    Peay, H.
    Hollin, I.
    Bridges, J.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S125 - S126
  • [4] Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis
    Ilene L. Hollin
    Holly L. Peay
    John F. P. Bridges
    The Patient - Patient-Centered Outcomes Research, 2015, 8 : 19 - 27
  • [5] Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis
    Hollin, Ilene L.
    Peay, Holly L.
    Bridges, John F. P.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (01): : 19 - 27
  • [6] Patient- and caregiver-reported impact of symptoms in Duchenne muscular dystrophy
    Rosero, Spencer
    Weinstein, Jennifer
    Seabury, Jamison
    Varma, Anika
    Dilek, Nuran
    Zizzi, Christine
    Coffey, Madeleine
    Greco, Brittany
    Heatwole, John
    Alexandrou, Danae
    Guntrum, Debra
    Ciafaloni, Emma
    Heatwole, Chad
    MUSCLE & NERVE, 2024, 70 (01) : 120 - 129
  • [8] Caregiver burden with Duchenne and Becker muscular dystrophy in Japan
    Ishizaki, M.
    Kobayashi, M.
    Nakamura, A.
    Maeda, Y.
    Ueyama, H.
    Matsumura, T.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [9] Duchenne muscular dystrophy and caregiver burden: a systematic review
    Landfeldt, Erik
    Edstroem, Josefin
    Buccella, Filippo
    Kirschner, Janbernd
    Lochmueller, Hanns
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2018, 60 (10): : 987 - +
  • [10] ADVANCING THE MEASUREMENT OF TREATMENT PREFERENCES IN DUCHENNE MUSCULAR DYSTROPHY
    Bridges, J. F.
    Tsai, J.
    Janssen, E. M.
    Fischer, R.
    Peay, H.
    VALUE IN HEALTH, 2017, 20 (05) : A225 - A225